Moderna, Inc. (MRNA)
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company's messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset has yet to be presented publicly.
Wall Street Breakfast Podcast: No Sprint For Nike Yet
Nike (NKE) faces persistent headwinds, with Q1 sales down 4% and China revenue plunging 22% year-over-year. Moderna (MRNA) will join the Nasdaq-100 replacing Warner Bros Discovery (WBD).
Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell
Moderna stock (NASDAQ: MRNA) rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking funds. The move follows a spectacular 2026 rally that has pushed Moderna more than 500% higher and transformed it from a post-pandemic recovery story into an oncology bet.
Nike, ON Semi, Moderna, and More Stocks That Explain Today's Market
Nike slumps after the retailer misses analysts' first-quarter earnings target and issues downbeat full-year guidance.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
Moderna (MRNA) closed the most recent trading day at $188.94, moving 1.89% from the previous trading session.
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) downgrade to Sell, a sign the market still prizes the company's cancer vaccine pipeline over the valuation warning.
Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year
Moderna's stock has been flying high lately. That has one group of analysts saying it's time to sell.
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is drawing attention Wednesday after Citigroup downgraded the biotech company to Sell from Hold, arguing that the recent rally has pushed the valuation well ahead of what its pipeline can reasonably support.
Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell.
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn't enough to justify the valuation.
Citi tells investors it's time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna's share price, according to Citi's analysts.
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
